World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
33674
World Ranking
13023
National Ranking
1217

Overview

Gordon J. S. Rustin is affiliated with Mount Vernon Hospital in the United Kingdom. Their research primarily focuses on medicine, with significant contributions in surgery, pulmonary and respiratory medicine, reproductive medicine, rheumatology, and obstetrics and gynecology. The main topics addressed in their work include testicular diseases and treatments, sarcoma diagnosis and treatment, ovarian cancer diagnosis and treatment, urologic and reproductive health conditions, intraperitoneal and appendiceal malignancies, renal cell carcinoma treatment, as well as adrenal and paraganglionic tumors.

They have contributed extensively to the scientific literature, with notable publications including:

  • Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994, 2023, Journal of Clinical Oncology
  • Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST), 2022, Journal of Clinical Oncology
  • Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial, 2021, ESMO Open
  • A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer, 2020, Gynecologic Oncology
  • Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial, 2020, Gynecologic Oncology

Their frequent co-authors include:

  • Johnathan Joffe
  • Fay Cafferty
  • Richard Kaplan
  • Robert Huddart
  • S.A. Sohaib

Research by Gordon J. S. Rustin has been published predominantly in the following venues:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • ESMO Open
  • European Journal of Cancer
  • Practical Radiation Oncology

Their work covers an extensive range of clinical and therapeutic areas involving oncology, especially focusing on cancers related to reproductive and urologic systems. Their research frequently addresses clinical trials and randomized studies offering insight into treatment efficacy and surveillance strategies in cancer care.

Best Publications

  • Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

    Anwar R. Padhani;Guoying Liu;Dow Mu-Koh;Thomas L. Chenevert

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Carboplatin or cisplatin

    A.H. Calvert;A. Horwich;E.S. Newlands;R. Begent

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

    Ajay K. Kakkar;Mark N. Levine;Zbigniew Kadziola;Nicholas R. Lemoine

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Gordon J.S. Rustin;Maria E.L. Van Der Burg;Clare L. Griffin;David Guthrie

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

    E. S. Newlands;G. R. Blackledge;J. A. Slack;G. J. Rustin

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

    R.T.D. Oliver;Mason;G.M. Mead;H. von der Maase

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

    G. J. S. Rustin;A. E. Nelstrop;P. Mcclean;M. F. Brady

  • Role of tumour markers in monitoring epithelial ovarian cancer.

    T Meyer;G J S Rustin

  • CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

    M.J. Duffy;J.M. Bonfrer;J. Kulpa;G.J.S. Rustin

  • Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study

    G. J. S. Rustin;A. E. Nelstrop;M. K. Tuxen;H. E. Lambert

  • Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

    Susan M. Galbraith;Ross J. Maxwell;Martin A. Lodge;Gillian M. Tozer

  • Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis

    Susan M Galbraith;Martin A Lodge;N Jane Taylor;Gordon J S Rustin

  • Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

    Gordon J.S. Rustin;Susan M. Galbraith;Helen Anderson;Michael Stratford

Frequent Co-Authors

Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Michael Friedlander
Michael Friedlander University of New South Wales
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Anwar R. Padhani
Anwar R. Padhani Northwood University
Clare L. Scott
Clare L. Scott Walter and Eliza Hall Institute of Medical Research
Mark Bower
Mark Bower Imperial College London
Gordon C Jayson
Gordon C Jayson University of Manchester
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Robert Huddart
Robert Huddart Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in exploring alternative healthcare careers beyond medical school, there are many flexible and accessible pathways available online. For those seeking advanced roles in nursing, direct msn programs online allow non-nurses to fast-track their education and enter the profession at a graduate level.

Entry into healthcare programs can vary in competitiveness. Some students might benefit from considering the easiest nursing programs to get into, which offer more inclusive admission criteria while still delivering quality education.

Not all healthcare careers require direct patient care. Medical billing and coding is a growth field with strong remote work potential. Many institutions offer online certificates and degrees, and you can find medical billing and coding schools with financial aid to help make your education more affordable.

Finally, some programs have streamlined testing requirements. If you're wondering “do i need to take the teas test for lpn?”—there are schools that no longer require the TEAS or HESI for admission, making it easier to begin your nursing journey.

Best Scientists Citing Gordon J. S. Rustin

Trending Scientists

Recently Published Articles